Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Pacing Clin Electrophysiol ; 23(5): 877-83, 2000 May.
Article in English | MEDLINE | ID: mdl-10833709

ABSTRACT

Three patients from different centers with pacemaker or ICD leads endocardially implanted in the left ventricle are described. All leads, two ventricular pacing leads and one ICD lead, were inserted through a patent foramen ovale or an atrial septum defect. The diagnosis was made 9 months, 14 months, and 16 years, respectively, after implantation. All patients had right bundle branch block configuration during ventricular pacing. Chest X ray was suggestive of a left-sided positioned lead except in the ICD patient. Diagnosis was confirmed with echocardiography in all patients. One patient with a ventricular pacing lead presented with a transient ischemic attack at 1-month postimplantation. During surgical repair of the atrial septum defect 14 months later, the lead was extracted and thrombus was attached to the lead despite therapy with aspirin. The other patients were asymptomatic without anticoagulation (9 months and 16 years after implant). No thrombus was present on the ICD lead at the time of the cardiac transplantation in one patient. We reviewed 27 patients with permanent leads described in the literature. Ten patients experienced thromboembolic complications, including three of ten patients on antiplatelet therapy. The lead was removed in six patients, anticoagulation with warfarin was effective for secondary prevention in the four remaining patients. In the asymptomatic patients, the lead was removed in five patients. In the remaining patients, 1 patient was on warfarin, 2 were on antiplatelet therapy, and in 3 patients the medication was unknown. After malposition was diagnosed, three additional patients were treated with warfarin. In conclusion, if timely removal of a malpositioned lead in the left ventricle is not preformed, lifelong anticoagulation with warfarin can be recommended as the first choice therapy and lead extraction reserved in case of failure or during concomitant surgery.


Subject(s)
Bundle-Branch Block/etiology , Defibrillators, Implantable , Equipment Failure Analysis , Heart Septal Defects, Atrial/complications , Heart Ventricles , Pacemaker, Artificial , Thromboembolism/etiology , Adolescent , Aged , Anticoagulants/administration & dosage , Bundle-Branch Block/diagnostic imaging , Bundle-Branch Block/therapy , Device Removal , Echocardiography , Electrocardiography , Electrodes, Implanted , Female , Heart Septal Defects, Atrial/diagnostic imaging , Heart Ventricles/diagnostic imaging , Humans , Long-Term Care , Male , Risk Factors , Thromboembolism/diagnostic imaging , Thromboembolism/therapy , Warfarin/administration & dosage
2.
Am J Cardiol ; 83(7): 1127-9, A9, 1999 Apr 01.
Article in English | MEDLINE | ID: mdl-10190533

ABSTRACT

Although the long-term prognosis for patients with a normal dobutamine stress echocardiographic result is good, most studies have focused on men. We assessed the long-term cardiac prognosis for women by reviewing the cases of 100 women who underwent dobutamine stress echocardiography for suspected coronary artery disease and found that women with a normal result have an excellent long-term cardiac prognosis.


Subject(s)
Coronary Disease/diagnostic imaging , Dobutamine , Echocardiography , Coronary Disease/therapy , Female , Follow-Up Studies , Humans , Middle Aged , Prognosis
3.
Tex Heart Inst J ; 26(1): 34-41, 1999.
Article in English | MEDLINE | ID: mdl-10217469

ABSTRACT

Congestive heart failure due to diastolic dysfunction is a common clinical entity, particularly in the elderly. As outlined, such patients fall into a larger group of all patients with CHF symptoms and normal systolic function. When finding "normal" systolic function, the clinician should embark upon a carefully outlined diagnostic work-up geared toward eliminating confounding or treatable contributing causes of dyspnea or typical CHF symptoms. The prognosis for CHF patients with primarily diastolic dysfunction is not as poor as for those with LV systolic dysfunction, although the prevalence, associated morbidity, and costs are great. In contrast to the large number of successful clinical trials that have guided treatment of LV systolic failure, an extremely limited number of trials have specifically addressed themselves to diastolic dysfunction. Marked symptomatic relief can often be provided with careful attention to tailored therapy, although little is known with regard to outcome. Refinements in noninvasive imaging methods and hemodynamic indices of diastolic function may lead to improved patient care.


Subject(s)
Diastole/physiology , Heart Failure/diagnosis , Systole/physiology , Ventricular Dysfunction, Left/diagnosis , Ventricular Function, Left/physiology , Heart Failure/physiopathology , Humans , Practice Guidelines as Topic , Prognosis , Ventricular Dysfunction, Left/physiopathology
4.
Tex Heart Inst J ; 25(2): 130-5, 1998.
Article in English | MEDLINE | ID: mdl-9654658

ABSTRACT

Prosthetic valve thrombosis is a well-known condition. Because surgical treatment of prosthetic valve thrombosis is associated with a high mortality rate, the use of thrombolysis as therapy for this condition has gained popularity in recent years. In this article, we discuss the cases of 3 patients who presented to our institution with left-sided prosthetic valve thrombosis between 1994 and 1997. All 3 patients presented with New York Heart Association functional class III or IV symptoms, and all were successfully treated with urokinase. The use of thrombolytic therapy for left-sided prosthetic valve thrombosis is associated with low mortality rates, and therefore is an attractive alternative to valve replacement or thrombectomy. However, the risk of embolic and hemorrhagic complications precludes the use of thrombolysis in patients with large thrombi and in those with New York Heart Association functional class I and II symptoms; for these patients, the risk associated with thrombolysis exceeds surgical mortality rates.


Subject(s)
Heart Valve Prosthesis , Plasminogen Activators/therapeutic use , Prosthesis Failure , Thrombolytic Therapy , Thrombosis/drug therapy , Urokinase-Type Plasminogen Activator/therapeutic use , Aged , Anticoagulants/therapeutic use , Echocardiography, Doppler , Echocardiography, Transesophageal , Female , Follow-Up Studies , Humans , Infusions, Intravenous , Male , Middle Aged , Plasminogen Activators/administration & dosage , Retrospective Studies , Thrombosis/diagnostic imaging , Thrombosis/etiology , Urokinase-Type Plasminogen Activator/administration & dosage , Warfarin/therapeutic use
5.
J Am Coll Cardiol ; 26(1): 152-8, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7797744

ABSTRACT

OBJECTIVES: This study sought to determine the prognostic yield and utility of transesophageal echocardiography in critically ill patients with unexplained hypotension. BACKGROUND: Transesophageal echocardiography is increasingly utilized in the intensive care setting and is particularly suited for the evaluation of hypotension; however, the prognostic yield of transesophageal echocardiography in these patients is unknown. METHODS: We prospectively studied 61 adult patients in the intensive care unit with sustained (> 60 min) unexplained hypotension. Both transthoracic and transesophageal echocardiography were performed, and results were immediately disclosed to the primary physician, who reported any resulting changes in management. Patients were classified on the basis of transesophageal echocardiographic findings into one of three prognostic groups: 1) nonventricular (valvular, pericardial) cardiac limitation to cardiac output; 2) ventricular failure; and 3) noncardiac systemic disease (hypovolemia or low systemic vascular resistance, or both). Primary end points were death or discharge from the intensive care unit. RESULTS: A transesophageal echocardiographic diagnosis of nonventricular limitation to cardiac output was associated with improved survival to discharge from the intensive care unit (81%) versus a diagnosis of ventricular disease (41%) or hypovolemia/low systemic vascular resistance (44%, p = 0.03). Twenty-nine (64%) of 45 transthoracic echocardiographic studies were inadequate compared with 2 (3%) of 61 transesophageal echocardiographic studies (p < 0.001). Transesophageal echocardiography contributed new clinically significant diagnoses (not seen with transthoracic echocardiography) in 17 patients (28%), leading to operation in 12 (20%). CONCLUSIONS: Transesophageal echocardiography makes a clinically important contribution to the diagnosis and management of unexplained hypotension and predicts prognosis in the critical care setting.


Subject(s)
Echocardiography, Transesophageal , Heart Diseases/diagnostic imaging , Hypotension/etiology , Ventricular Dysfunction/complications , Adult , Aged , Aged, 80 and over , Critical Illness , Female , Heart Diseases/complications , Heart Diseases/mortality , Humans , Hypotension/diagnostic imaging , Hypotension/mortality , Intensive Care Units , Male , Middle Aged , Prognosis , Prospective Studies , Survival Rate , Vascular Resistance , Ventricular Dysfunction/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...